Unknown

Dataset Information

0

Pharmacokinetics of glycopyrronium/formoterol fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in patients with moderate-to-very severe COPD.


ABSTRACT: Purpose:The efficacy and tolerability of GFF MDI (Bevespi Aerosphere®), a fixed-dose combination of glycopyrronium (GP)/formoterol fumarate dihydrate (FF) 14.4/10 ?g (equivalent to glycopyrrolate/formoterol fumarate 18/9.6 ?g) delivered by metered dose inhaler (MDI) using innovative co-suspension delivery technology, has been investigated in a Phase III clinical trial program (NCT01854645, NCT01854658, NCT01970878) in patients with COPD. Here, we present findings from a pharmacokinetic (PK) sub-study of NCT01854645 (PINNACLE-1). Methods:PINNACLE-1 was a multicenter, randomized, double-blind, parallel-group, 24 wk chronic-dosing, placebo- and active-controlled study. The PK sub-study assessed the systemic accumulation of glycopyrronium and formoterol following administration of GFF MDI 14.4/10 ?g, GP MDI 14.4 ?g, or FF MDI 10 ?g (all BID) for 12 wks. Plasma for PK analysis was collected for up to 12 h after dosing, on Day 1 and Week 12. Results:Of 2,103 patients randomized in PINNACLE-1, 292 participated in the PK sub-study. The plasma concentration-time profiles of glycopyrronium were similar following treatment with GFF MDI or GP MDI, both after single dosing and at Week 12. Accumulation at Week 12 relative to Day 1 was up to 2.30-fold for glycopyrronium. The plasma concentration-time profiles of formoterol were similar following treatment with GFF MDI or FF MDI, both after single dosing and at Week 12. Accumulation at Week 12 relative to Day 1 was up to 1.62-fold for formoterol. Conclusion:Overall, the results have characterized the accumulation of glycopyrronium and formoterol associated with GFF MDI, GP MDI, and FF MDI, and indicated that there were no meaningful PK interactions, whether drug-drug or due to formulation, between glycopyrronium and formoterol following treatment with GFF MDI formulated using co-suspension delivery technology.

SUBMITTER: Ferguson GT 

PROVIDER: S-EPMC5868634 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature

altmetric image

Publications

Pharmacokinetics of glycopyrronium/formoterol fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in patients with moderate-to-very severe COPD.

Ferguson Gary T GT   Rodriguez-Roisin Roberto R   Reisner Colin C   Maes Andrea A   Siddiqui Shahid S   Martin Ubaldo J UJ  

International journal of chronic obstructive pulmonary disease 20180321


<h4>Purpose</h4>The efficacy and tolerability of GFF MDI (Bevespi Aerosphere<sup>®</sup>), a fixed-dose combination of glycopyrronium (GP)/formoterol fumarate dihydrate (FF) 14.4/10 μg (equivalent to glycopyrrolate/formoterol fumarate 18/9.6 μg) delivered by metered dose inhaler (MDI) using innovative co-suspension delivery technology, has been investigated in a Phase III clinical trial program (NCT01854645, NCT01854658, NCT01970878) in patients with COPD. Here, we present findings from a pharma  ...[more]

Similar Datasets

| S-EPMC5947839 | biostudies-literature
| S-EPMC7184113 | biostudies-literature
| S-EPMC7814657 | biostudies-literature
| S-EPMC6124470 | biostudies-literature
| S-EPMC6664772 | biostudies-literature
| S-EPMC6016010 | biostudies-literature
| S-EPMC6939402 | biostudies-literature
| S-EPMC7140742 | biostudies-literature
| S-EPMC6661743 | biostudies-literature
| S-EPMC8496011 | biostudies-literature